7. Incyte Corporation (NASDAQ:INCY)
Incyte Corporation is advancing its pipeline to offset future patent expirations while expanding into new treatment areas. On April 15, H.C. Wainwright reiterated a Buy rating and $135 price target, highlighting the potential of povorcitinib.
The drug is being positioned for earlier use in hidradenitis suppurativa, rather than as a later-stage treatment. This shift could significantly expand its addressable market. The firm cited discussions with a specialist managing around 700 patients annually, with approximately 80% classified as moderate to severe cases.
At the AAD 2026 Congress, Incyte presented 54-week data from the Phase 3 STOP-HS1 and HS2 studies. Results showed increasing HiSCR50 response rates over time across both initial and crossover patient groups, confirming sustained efficacy.
Analysts believe the expanding pipeline can offset the expected $3 billion revenue gap from ruxolitinib patent expiry by 2028. The focus now is execution—bringing new therapies to market before legacy revenue declines.
Click next to see the following stock...
